Table 2.
Changes in the components of the primary from baseline to the end of 3-month follow-up.
| Variable | Furosemide | Torasemide | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| On admission | 3-month follow up | P | On admission | 3-month follow up | P | |
| ZOE® Fluid Status Monitor [Ohm] | 17 (15–24) | 18 (15–23) | 0.68 | 18 (15–24) | 17 (15–19) | 0.05 |
| NYHA class | 3 (2–3) | 2 (1–3) | 0.37 | 3 (2–4) | 2 (2–3) | 0.18 |
| 6MWT [m] | 309 (172–450) | 320 (120–454) | 0.10 | 243 (120–432) | 340 (100–500) | 0.29 |
Values are showed as median (interquartile range); NYHA — New York Heart Association; 6MWT — six-minute walk test